References
- Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009; 27:Suppl 2 B20 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.04.067; PMID: 19477053
- Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, et al, Meningococcal Reference Unit. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55:887 - 96; http://dx.doi.org/10.1099/jmm.0.46288-0; PMID: 16772416
- Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011; 11:969 - 85; http://dx.doi.org/10.1517/14712598.2011.585965; PMID: 21615224
- Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287:1816 - 20; http://dx.doi.org/10.1126/science.287.5459.1816; PMID: 10710308
- Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al, V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379:617 - 24; http://dx.doi.org/10.1016/S0140-6736(11)61713-3; PMID: 22260988
- Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al, European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573 - 82; http://dx.doi.org/10.1001/jama.2012.85; PMID: 22318278
- Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010; 107:19490 - 5; http://dx.doi.org/10.1073/pnas.1013758107; PMID: 20962280
- Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. [Epub ahead of print] Lancet Infect Dis 2013; 13:416 - 25; http://dx.doi.org/10.1016/S1473-3099(13)70006-9; PMID: 23414709
- Anderson AS, Jansen KU, Eiden J. New frontiers in meningococcal vaccines. Expert Rev Vaccines 2011; 10:617 - 34; http://dx.doi.org/10.1586/erv.11.50; PMID: 21604983
- Granoff DM. European Medicines Agency Recommends Approval of a broadly Protective Vaccine against serogroup B meningococcal disease. [Epub ahead of print] Pediatr Infect Dis J 2012; PMID: 23263177